Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses telogen effluvium, a common form of hair loss, and reports no new clinical results; the authors outline possible causes, typical prognosis, and management strategies.

Telogen effluvium is hair loss caused by disruption of the normal hair cycle.

This article discusses telogen effluvium in women, its causes, and typical diagnostic methods, but reports no new research findings on clinical outcomes or treatments.

This review discusses the phases of the human hair cycle and highlights the importance of identifying factors that disturb it, but reports no new clinical findings.

This study found that FGF18 is crucial for regulating hair follicle rest and growth phases, as its absence in mice leads to a shorter resting phase and rapid hair cycling.

Telogen effluvium is a common hair loss condition where many hairs enter the resting phase, often not noticeable until significant loss occurs, and treatment focuses on the underlying cause.

Mimicking growth factors in a topical solution can prolong hair growth phase and reduce hair loss without side effects.

This article discusses telogen effluvium, a condition where a large number of scalp hairs prematurely enter the shedding phase, and reports no new clinical results; the authors emphasize the range of potential underlying causes.

This article discusses how metabolic imbalances can trigger telogen effluvium by causing hair follicles to prematurely enter the shedding phase, and includes no new research findings.

This study found that combining photobiomodulation therapy with minoxidil significantly improved hair quality and reduced telogen-phase hair counts more effectively than minoxidil alone in women with female pattern hair loss over a shorter 12.5-week period.

This article is a case report on severe hair loss due to telogen effluvium occurring during inpatient rehabilitation and does not provide new clinical results.

In this study, researchers found that microRNAs and specific target genes, such as MiR-195 and genes like CHP1, SMAD2, FZD6, and SIAH1, play significant roles in regulating hair follicle initiation in cashmere goats.

This study found that macrophage-stimulating protein (MSP) enhanced hair growth in both human hair follicles cultured in vitro and in mice through the promotion of anagen phase induction.

This review discusses "follicular hypoglycania" as a potential pathology in hair growth disorders and reports that proteoglycan replacement therapy may improve hair loss treatments, though it presents no new clinical trial results.

This study found that hair follicles on the anterior scalp may be more vulnerable to acute telogen effluvium than those on the occipital scalp.

This study in Italy observed telogen effluvium and trichodynia as common hair-related complications following COVID-19 infection, raising questions about underlying hair follicle biology and potential receptor involvement.

This article describes a clinical case of a 67-year-old patient with telogen effluvium treated with a supplement containing amino acids, vitamin E, iron, and Serenoa repens, but reports no new clinical findings.

This study found that overexpression of erythropoietin disrupted hair growth in mice by affecting dermal fat lipogenesis and lipolysis, leading to poor hair follicle development and truncal alopecia.

In this study, telogen effluvium, a common form of hair loss linked to changes in the hair cycle, is examined with a focus on diagnostic methods and effective treatment options, noting that 34.2% of patients experience trichodynia.

This article describes telogen effluvium as diffuse cyclic hair loss in women caused by systemic stresses, diseases, or physiological situations, but reports no new clinical results.

Telogen Effluvium is a condition where more hair than usual falls out after stress or fever.

This case study observed that discontinuing risperidone reduced elevated prolactin levels and improved hair thinning in a 77-year-old woman, suggesting risperidone-associated telogen effluvium as a consideration in similar cases.

This clinical trial found that topical application of Sandalore® 1% significantly reduced hair shedding and increased hair volume in women with telogen effluvium compared to placebo.

This study found that nutritional supplementation improved hair loss in women with telogen effluvium, showing a significant increase in anagen hairs and reduction in telogen hairs after three months.

This technical report from the European Food Safety Authority responds to comments on its previous scientific opinion regarding a health claim about spermidine and hair growth, reporting no new experimental results.

This text does not provide a research abstract or study findings but outlines a website's use of cookies and offers access to medical publications and articles.

This study found that telogen effluvium occurred in two subjects taking 500 mg of mefloquine weekly, and gastrointestinal intolerance was observed at higher doses in additional acute studies.

This study observed that in men with androgenetic alopecia, frontal hair regions showed reduced density, diameter, and growth rate compared to occipital regions, worsening with advanced stages.

This study found that 17-beta-estradiol inhibits hair growth in mice by blocking hair follicles in the telogen phase, whereas an estrogen receptor antagonist promotes hair growth by initiating anagen.

This study sequenced and analyzed the goat skin transcriptome, revealing genes involved in signal transduction and cell communication that are differentially expressed during hair growth phases, providing insights for Cashmere goat breeding.